Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,110.3
-17.4 (-0.56%)

 

  • STI Straits Times Index
    3,110.3
    -17.4 (-0.56%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,609.3
    6.9 (0.43%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,179.3
    130.6 (0.50%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,897.4
    14.0 (0.49%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,710.9
    82.9 (0.40%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,255.6
    16.4 (0.26%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,948.3
    -2.7 (-0.14%)
    Index delayed 20 minutes
  • XAO XAO
    6,614.3
    21.3 (0.32%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 728.4M
  • Value: 924.6M
  • Rise: 102
  • Fall: 203
  • Unch: 530

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
Rex Intl0.083+0.007
YZJ Shipbldg SGD0.915-0.015
ThaiBev0.935+0.005
Mapletree NAC Tr1.310-0.030
SingTel3.250+0.010
TEE Intl0.062-0.004
CapitaMall Trust2.640+0.020
HPH Trust USD0.167-0.010
SPH2.040-0.090

World Indices

World Indices
Name Last Change
Nasdaq 7,991.4 -28.8
HSI 26,179.3 +130.6
HSCEI 10,194.7 +71.8
Jakarta 6,255.6 +16.4
Nikkei 225 20,710.9 +82.9
SSE Comp 2,897.4 +14.0
Shanghai A 3,035.4 +14.7
Shanghai B 264.6 +0.3
PSE Comp 0.0
KOSPI 1,948.3 -2.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

MYOVANT SCIENCES LTD MYOVANT SCIENCES LTD.
Updated on 22 Aug 2019 (End of trading day)
Last (USD): 7.700 Change: -0.230 High: 8.000 Remarks: -
Change (%): -2.90 Low: 7.540
Open 7.900 Yesterday's Close 7.930000000000001
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 179,183 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -3.05224 Trailing EPS (USD) e -3.11662 NAV (USD) b 0.8878
PE a - Trailing PE f - Price / NAV b 8.6731
Dividend (USD) d - Cash In Hand (USD) g 2.5299 Issued & Paid-up Shares c 89,623,000
Dividend Yield (%) d - Price / Cash In Hand g 3.044 Treasury Shares h -
Beta - 75 Daysi -2.164 R-Squared - 75 Days(%)i 1.55 Market Cap (M) 690.097
Beta - 500 Daysi 0.015 R-Squared - 500 Days (%)i 0.01 Enterprise Value (M) 573.663
Piotroski F Score 0 Exchange Code MYOV Par Value ( $ ) n.a.
52 Weeks Volatility (%) 68.05 Free Float (%) 43.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 05 Jun 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 24 Oct 2016.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference MYOVANT SCIENCES LTD NYSE 690.097 - - 8.6731 -
Industry Biotechnology NYSE 4,384.457 678.548 39.657 4.2411 0.720
Local Peer AGILENT TECHNOLOGIES INC NYSE 22,669.338 71.739 21.147 4.7755 0.836
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,146.560 34.235 - 2.1707 -
Local Peer KADMON HLDGS INC NYSE 339.644 - - 3.4079 -
Local Peer ARCUS BIOSCIENCES INC NYSE 311.773 - - 1.1875 -
Local Peer ENZO BIOCHEM INC NYSE 149.329 - 70.705 1.6410 -
Global Peer AMGEN INC NASDAQ 121,991.177 14.533 15.329 11.3017 2.725
Global Peer GILEAD SCIENCES INC NASDAQ 81,331.419 14.910 13.658 3.5962 3.594
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 108,005.681 40.257 40.257 14.4332 1.124
Global Peer CELGENE CORP NASDAQ 67,833.601 16.766 12.869 6.7489 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 47,356.128 22.589 21.380 9.3405 -
Global Peer BIOGEN INC NASDAQ 42,802.771 9.661 8.085 3.3045 -
Global Peer ILLUMINA INC NASDAQ 42,421.260 51.357 45.225 9.7925 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,421.031 13.263 15.668 3.3232 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,689.792 356.825 20.763 2.7244 -
Other Global Peers INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), EXACT SCIENCES CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), WUXI BIO (HKEx), SEATTLE GENETICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), Lonza (SGX), GENSCRIPT BIO (HKEx), ACADIA PHARMACEUTICALS INC (NASDAQ), 3SBIO (HKEx), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), ALKERMES PLC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), OPKO HEALTH INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OMEROS CORP (NASDAQ), INTREXON CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), FRONTAGE (HKEx), NANOSTRING TECHNOLOGIES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), VIVA BIOTECH (HKEx), HOMOLOGY MEDICINES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CYTOKINETICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), HAOHAI BIOTEC (HKEx), MACROGENICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), NEXTCURE INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CORTEXYME INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), AVROBIO INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), ASCLETIS-B (HKEx), RETROPHIN INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AVITA MEDICAL LTD (ASX), AURINIA PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), INTRA-CELLUAR THERAPIES INC (NASDAQ), CKLIFE SCIENCES (HKEx), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), SINOVAC BIOTECH (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), AGENUS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RESTORBIO INC (NASDAQ), MEDICINOVA INC (NASDAQ), ESSEX BIO-TECH (HKEx), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), XBIOTECH INC (NASDAQ), NEXT SCIENCE LTD (ASX), REPLIMUNE GROUP INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), CASI PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), RECRO PHARMA INC (NASDAQ), GERON CORP (NASDAQ), LEE'S PHARM (HKEx), SYNDAX PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), EVOFEM BIOSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), DPHARMA (Bursa), CHIASMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), ARDELYX INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ATHERSYS INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), CUE BIOPHARMA INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), AFFIMED N V (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), PFENEX INC (NYSE American), NOVAVAX INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), LEXICON PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), IMV INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), UNI-BIO GROUP (HKEx), NANTKWEST INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), BBI LIFE SCI (HKEx), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), AVEO PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), TOCAGEN INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), VERASTEM INC (NASDAQ), SYNLOGIC INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), SAVARA INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), TREVENA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), CORREVIO PHARMA CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), PORT (SET), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), CEL-SCI CORP (NYSE American), VTV THERAPEUTICS INC (NASDAQ), IBIO INC (NYSE American), INFLARX N V (NASDAQ), ORGENESIS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), EQUILLIUM INC (NASDAQ), CURIS INC (NASDAQ), ARAVIVE INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), COHBAR INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), INMUNE BIO INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), PHYLOGICA LIMITED (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), UNUM THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), IMMUTEP LTD (ASX), SURFACE ONCOLOGY INC (NASDAQ), HEMISPHERX BIOPHARMA INC (NYSE American), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VERMILLION INC (NASDAQ), IMUGENE LIMITED (ASX), T2 BIOSYSTEMS INC (NASDAQ), CT ENTERPRISE (HKEx), SYNTHETIC BIOLOGICS INC (NYSE American), IVERIC BIO INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), REGENT PACIFIC (HKEx), BELLICUM PHARMACEUTICALS (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), ORTHOCELL LIMITED (ASX), VASCULAR BIOGENICS LTD (NASDAQ), EVOGENE LTD (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), ZELDA THERAPEUTICS LTD (ASX), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), ZAFGEN INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), BIOTRON (ASX), RHINOMED LIMITED (ASX), SOPHIRIS BIO INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), SENESTECH INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), AEVI GENOMIC MEDIC (NASDAQ), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), BIOCEPT INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ORAGENICS INC (NYSE American), SOLIGENIX INC (NASDAQ), MEMPHASYS LTD (ASX), ISORAY INC (NYSE American), CELLECTAR BIOSCIENCES INC (NASDAQ), HISTOGENICS CORP (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), CO DIAGNOSTICS INC (NASDAQ), VICAL INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PRECIPIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), REGENEUS LTD (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), BIONOMICS LTD (ASX), ADALTA LTD (ASX), DARE BIOSCIENCE INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), TROVAGENE INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), Suntar Eco-City^ (SGX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), ATYR PHARMA INC (NASDAQ), CELLMID LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), ENDRA LIFE SCIENCES INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), VAXART INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), BIOXYNE LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), HAO WEN HLDGS (HKEx), REXAHN PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), CYCLACEL PHARMA IN (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ADVAXIS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), MGRC (Bursa), AURIS MEDICAL HOLDING LTD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), MEGASUN (Bursa), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), CCP TECHNOLOGIES LTD (ASX), QT Vascular (SGX), TBG DIAGNOSTICS LTD (ASX), NANOLLOSE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), BPH ENERGY LIMITED (ASX), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), MEDIBIO LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), ALCHEMIA LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.700
+10.00 %
10 Days -+0.210
+2.80 %
20 Days -+0.480
+6.65 %
Medium Term Return 3 Months --4.730
-38.05 %
6 Months --13.710
-64.04 %
1 Year --14.040
-64.58 %
Long Term Return 2 Years --6.250
-44.80 %
Annualised Return Annualised --
-25.71 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 6.600 - 27.450 Change From 1 Year Low +1.100 % Change From 1 Year Low (%) +16.67
Change From 1 Year High -19.750 % Change From 1 Year High (%) -71.95
2 Years Range 6.600 - 27.450 Change From 2 Years Low +1.100 % Change From 2 Years Low (%) +16.67
Change From 2 Years High -19.750 % Change From 2 Years High (%) -71.95
5 Years Range 6.600 - 27.450 Change From 5 Years Low +1.100 % Change From 5 Years Low (%) +16.67
Change From 5 Years High -19.750 % Change From 5 Years High (%) -71.95
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Aug 2019 7.900 8.000 7.540 7.700 179,183 -
21 Aug 2019 7.880 8.000 7.680 7.930 122,952 -
20 Aug 2019 7.940 8.410 7.790 7.870 275,866 -
19 Aug 2019 7.650 8.120 7.250 7.820 316,017 -
16 Aug 2019 7.120 7.280 6.864 7.000 268,108 -
15 Aug 2019 7.170 7.210 6.830 7.000 254,120 -
14 Aug 2019 7.200 7.280 6.860 7.160 157,526 -
13 Aug 2019 7.210 7.295 7.110 7.180 106,131 -
12 Aug 2019 7.470 7.645 7.200 7.225 100,913 -
09 Aug 2019 7.310 7.650 7.280 7.490 164,457 -
08 Aug 2019 7.280 7.350 7.060 7.280 134,139 -
07 Aug 2019 6.660 7.350 6.650 7.290 347,225 -
06 Aug 2019 6.870 7.010 6.660 6.950 258,095 -
05 Aug 2019 6.800 7.040 6.630 6.810 283,753 -
02 Aug 2019 7.040 7.040 6.700 6.900 255,081 -
01 Aug 2019 7.190 7.260 6.950 7.050 220,870 -
31 Jul 2019 6.970 7.260 6.810 7.200 384,507 -
30 Jul 2019 6.920 7.065 6.600 6.940 143,362 -
29 Jul 2019 7.250 7.250 6.860 6.950 223,047 -
26 Jul 2019 7.520 7.520 7.090 7.220 224,846 -
25 Jul 2019 7.920 7.922 7.430 7.470 177,329 -
24 Jul 2019 8.000 8.020 7.710 7.930 284,447 -
Summary
Current 2 Weeks
(09 Aug 2019 to 22 Aug 2019)
7.310 8.410 6.830 7.700 1,945,273 -
Previous 2 Weeks
(26 Jul 2019 to 08 Aug 2019)
7.520 8.410 6.830 7.280 2,474,925 -
4 Weeks from
(27 Jun 2019 to 25 Jul 2019)
8.850 9.340 6.830 7.470 5,051,939 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.